Inventiva SA
inventivapharma.comWhat Do They Do?
Develops an oral small-molecule therapy for MASH, a chronic liver disease, and earlier-stage treatments for cancer.
20-F for FY2025, filed Apr 8, 2026
Who Are Their Customers?
Pharmaceutical partners license development and commercialization rights for particular territories; CTTQ covers China, and Hepalys covers its territory. The company has also sold drug-related assets to Biossil.
20-F for FY2025, filed Apr 8, 2026
How Are They Changing?
Focused development on lanifibranor
The older report described a broader pipeline that included odiparcil, oncology and other early-stage programs, alongside lanifibranor. The latest report describes development focused exclusively on lanifibranor, with non-lanifibranor research discontinued and odiparcil assets sold.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Apr 8, 2026We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of…View ↗
Odiparcil for the Treatment of MPS. Our second clinical-stage asset is odiparcil, which we were previously developing for the treatment of…View ↗
Discovery Engine. We have a scientific team of approximately 90 people with deep biology, medicinal and computational chemistry…View ↗
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of MASH. We…View ↗
Odiparcil. We were previously developing odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare…View ↗
Discovery Engine. As of the end of February 2026, we have a development team of 47 people, as well as one position dedicated to research…View ↗
Who Do They Compete With?
Competes with Madrigal, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Akero Therapeutics, GSK, Roche, 89bio, Sagimet, Boston Pharmaceuticals, Altimmune, AstraZeneca, NorthSea, Terns, Viking, BMS, Pfizer, Regeneron, and Gilead Sciences
20-F for FY2025, filed Apr 8, 2026In March 2024, Madrigal received FDA approval of Rezdiffra for the treatment of patients with MASH with moderate to advanced liver fibrosis…View ↗
Loading...
